Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has extended its psychedelic-assisted clinical research to Phoenix and expanded its facility footprint in the United States.
The psychedelic-assisted therapy company announced Friday its new site is the third clinical trial research site in the United States. The company will offer clinical research management services focused on advancing psychedelic science through its Cedar Clinical Research (CCR).
The new site is situated in a facility that is adjacent to one of Numinus’ wellness clinics. The first clinical trial to be conducted at the new site will start in early March, starting with a site inspection visit, followed by the recruitment phase later in the same month.
“By expanding into Phoenix, we can scale our clinical research capabilities, allowing us to offer our current clients faster services and an expanded network of participants while welcoming a growing list of biotech and psychedelic organizations,” says Paul Thielking, Chief Research Officer, Numinus.
“The site is fully staffed – drawing on our clinic base of renowned researchers and practitioners, so we can start operations as soon as possible.”
By the end of November last year, CCR managed 14 clinical trials involving 191 participants. The trials are for third-party biotech and psychedelics sector firms.
Read more: Numinus develops psilocybin-infused tea bag for clinical studies
Read more: Numinus launches ketamine-assisted therapy in Toronto
“The addition of this new clinical research site further cements Numinus as one of the leading research platforms for the sector’s companies and institutions who sponsor clinical trials in the mental health and psychedelic space, allowing them to leverage our extensive resources and management offering,” says Payton Nyquvest, CEO and Founder, Numinus.
“Ultimately, this allows Numinus to support the growing body of research in the mental health and psychedelic space as we all work towards the goal of more indication-based evidence and safety data.”
Vancouver-based Numinus Wellness promotes mental healthcare and provides access to safe and evidence-based psychedelic-assisted therapies to help people heal and improve their overall well-being.
The organization’s approach involves combining psychedelic production, research, and clinical care to facilitate a “transformative shift” towards healing, rather than just managing symptoms of various conditions such as depression, anxiety, trauma, pain, and substance use.
Company stock stayed flat on Friday at $0.24 on the Toronto Securities Exchange.